Juvenile Myelomonocytic Leukemia (JMML) Cell Models for Research

Juvenile myelomonocytic leukemia (JMML) is a rare, aggressive myeloproliferative/myelodysplastic neoplasm of early childhood, accounting for approximately 1-2% of childhood leukemias. The annual incidence is estimated at 1.2 per million children in the United States, with a median age at diagnosis of 2 years (WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2016). JMML is characterized by excessive proliferation of monocytic and granulocytic precursors, leading to organ infiltration, splenomegaly, and cytopenias. Without hematopoietic stem cell transplantation (HSCT), the 5-year overall survival is less than 20%, but with HSCT, survival improves to 50-60% (NCI PDQ). Relapse remains the leading cause of death, with a cumulative incidence of 30-40% post-transplant. Key risk factors include germline mutations in NF1, PTPN11, CBL, and RAS pathway genes, as well as Noonan syndrome and neurofibromatosis type 1. The disease is universally fatal if untreated, underscoring the urgent need for targeted therapies.

JMML is an ideal model for studying RAS/MAPK signaling dysregulation because over 90% of patients harbor mutations in genes of the RAS pathway, making it a near-homogeneous genetic disease. This genetic simplicity allows for precise modeling of oncogenic drivers and facilitates the development of targeted therapies. Public datasets, such as those from the COSMIC database and the International JMML Registry, provide extensive genomic and clinical data. Open questions include the role of cooperating mutations, the mechanisms of disease progression, and the development of resistance to targeted inhibitors. Gene-edited cell models are essential for dissecting these mechanisms and for preclinical drug testing.

JMML is driven primarily by constitutive activation of the RAS/MAPK signaling pathway. The following steps outline the key pathogenic cascade:

1. Germline or somatic mutations in genes encoding RAS pathway components (e.g., PTPN11, NF1, NRAS, KRAS, CBL) lead to hyperactivation of RAS.

2. Activated RAS recruits RAF kinases (e.g., BRAF, CRAF) to the membrane, initiating a phosphorylation cascade.

3. MEK1/2 phosphorylates ERK1/2, which translocates to the nucleus and activates transcription factors (e.g., ELK1, c-Fos) that promote cell proliferation and survival.

4. Constitutive ERK signaling leads to hypersensitivity of myeloid progenitors to granulocyte-macrophage colony-stimulating factor (GM-CSF), a hallmark of JMML.

5. The resulting uncontrolled myeloproliferation causes accumulation of immature monocytes and granulocytes in blood, bone marrow, and organs.

Additionally, the PI3K/AKT pathway is often co-activated, contributing to apoptosis resistance and enhanced cell survival.

The following table summarizes the most frequent genetic alterations in JMML, based on data from COSMIC and TCGA (where applicable). Note that TCGA does not include JMML, but COSMIC and published studies provide comprehensive data.

Data sources: COSMIC (v98), Loh et al. (2019) Nat Rev Cancer, and Niemeyer et al. (2018) Blood.

Beyond the RAS/MAPK pathway, several other signaling networks are deregulated in JMML:

• • GM-CSF receptor signaling: Hypersensitivity to GM-CSF is a hallmark; the receptor (CSF2RA/CSF2RB) activates JAK2/STAT5 and RAS/MAPK pathways.
• • PI3K/AKT/mTOR: Co-activation promotes cell survival and proliferation.
• • JAK/STAT pathway: Aberrant activation in some cases, especially with CBL mutations.
• • NF-κB: Chronic inflammation and cytokine production.
• • Epigenetic regulators: Mutations in TET2, DNMT3A, and ASXL1 affect DNA methylation and chromatin remodeling.

Key nodes for therapeutic targeting include MEK1/2, PI3K, and JAK2.

Several cell lines are used for JMML research, though none are truly JMML-specific. The following table lists commonly used myeloid leukemia cell lines with relevant mutations:

Organoid models: 3D bone marrow organoids are being developed to recapitulate the hematopoietic microenvironment and JMML cell interactions. They allow for testing of drug responses in a more physiologically relevant context.

Animal models are critical for studying JMML pathogenesis and testing therapies. Examples include:

• • Patient-derived xenografts (PDX): Immunodeficient mice (e.g., NSG) engrafted with JMML patient cells. They recapitulate the disease phenotype and are used for drug efficacy studies.
• • Genetically engineered mouse models (GEMMs):
• • Nf1 knockout mice (Nf1fl/fl; Mx1-Cre) develop a myeloproliferative disorder resembling JMML.
• • Knock-in mice with Ptpn11 mutations (e.g., Ptpn11D61Y) show JMML-like features.
• • KrasG12D and NrasG12D knock-in mice develop myeloproliferative neoplasms.
• • Induced models: CRISPR-engineered human hematopoietic stem cells (HSPCs) with RAS pathway mutations can be transplanted into mice to generate JMML-like disease.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise mutations in JMML-associated genes. These models are invaluable for studying the functional consequences of specific mutations and for drug screening. Examples include:

• • TP53 knockout cell lines (e.g., in THP-1 or K562) to study p53 loss in therapy resistance.
• • KRAS G12D knock-in cell lines (e.g., in TF-1 or MUTZ-8) to model constitutive RAS activation.
• • PTPN11 E76K knock-in lines to study SHP2 gain-of-function.
• • NF1 knockout lines to model loss of RasGAP activity.

These models are commercially available from various sources and are sequence-verified, ensuring reproducibility. They accelerate research by providing consistent, genetically defined systems for functional genomics, drug screening, and target validation.

Gene-edited cell lines are used to validate the role of specific genes in JMML pathogenesis. For example:

• • Knockout of NF1 in a myeloid cell line leads to increased RAS-GTP levels and enhanced proliferation, confirming its tumor suppressor role.
• • Knock-in of PTPN11 E76K in TF-1 cells results in GM-CSF hypersensitivity, recapitulating a hallmark of JMML.
• • CRISPR screens using a library of sgRNAs targeting RAS pathway genes can identify synthetic lethal interactions or genes that modulate drug sensitivity.

Isogenic pairs (wild-type vs. mutant) are ideal for high-throughput drug screening. For instance:

• • Screening MEK inhibitors (e.g., trametinib) in KRAS G12D knock-in vs. wild-type cells can identify selective toxicity.
• • Resistance studies: Chronic exposure to a drug can select for resistant clones; CRISPR editing can introduce candidate resistance mutations to confirm their role.
• • Combination screening: Gene-edited cells can be used to test synergistic drug combinations, such as MEK inhibitors with PI3K inhibitors.

CRISPR-based synthetic lethality screens can identify novel biomarkers and therapeutic targets. For example:

• • A screen in NF1 knockout cells may reveal vulnerabilities that are specific to NF1 loss, leading to new drug targets.
• • Gene-edited cells can be used to identify biomarkers of drug response by correlating mutation status with drug sensitivity.
• • Secreted proteins from mutant cells can be profiled to discover serum biomarkers for disease monitoring.

The following table lists key public databases for JMML research: